ILU.F Illumina Inc

Healthcare Biotechnology Frankfurt Exchange
189.20 EUR
Close of Nov 12, 2026
95.35 274.95
Market cap
EUR 28.6B
P/E
37.8x
P/B
10.52x
ROE
22.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is ILU.F undervalued?

Graham number

The Graham number of Illumina Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Illumina Inc fundamental analysis

No fundamental analysis for Illumina Inc yet.

Illumina Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Illumina Inc

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific gene…

Full company profile